3 Stocks I'm Not Selling No Matter What the Market Does for the Next 20 Years

The common thread here is not “quality” in the generic sense; it is monetization durability. BRK.B is the clearest defensive compounder because its float and operating mix should outperform in a drawdown, while ISRG and NVDA are higher-beta cash-flow machines whose moats are widening through installed-base economics and ecosystem lock-in. The second-order setup is that capital is likely to keep flowing toward businesses where recurring revenue and pricing power can survive a recessionary scare, which argues for owning the leaders and fading economically exposed imitators rather than betting on broad thematic baskets.

The market is still underestimating how much of NVDA’s runway depends on capex concentration rather than end-demand. If hyperscaler spending pauses for even one or two quarters, the stock can derate faster than fundamentals because expectations are now embedded in the entire AI supply chain; that creates a sharp but potentially temporary air pocket. ISRG has a different risk: adoption is structurally strong, but hospitals can stretch replacement cycles if financing costs stay elevated, so the near-term multiple support is more sensitive to rates than the headline procedure growth suggests.

Contrarianly, the “reasonable valuation” framing may be too complacent for NVDA and ISRG if their historical multiples were set during periods of lower rates and less crowded ownership. The better asymmetry is probably in BRK.B as a cash-rich volatility absorber and in relative-value structures that express quality-vs-cyclicals rather than outright index beta. If a broad market correction hits in the next 1-3 quarters, these names should still outperform, but NVDA is the one most likely to experience the largest multiple compression before fundamentals reassert.